Clinical Trials Browser

Phase 1/2 × Spironolactone × Other hematologic neoplasm × Clear all

NCT03867682 2023-08-04

Venetoclax and Lintuzumab-Ac225 in AML Patients

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute